Evidence map›Paper›PMID 29973979›Full record

ArticlePathology research international2018

Prognostic Factors in Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis with Severe Glomerular Sclerosis: A National Registry-Based Cohort Study.

Rune Bjørneklett, Vilde Solbakken, Leif Bostad, Anne-Siri Fismen

Open access · hybridAbstract read
In one paragraph

Article in Pathology research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Rune BjørneklettDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.ORCID 0000-0001-6637-5743
Vilde SolbakkenDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.ORCID 0000-0002-9517-6871
Leif BostadDepartment of Pathology, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0003-4198-5136
Anne-Siri FismenFaculty of Health and Social Sciences, Western Norway University of Applied Sciences, Bergen, Norway.
Haukeland University Hospital · NOUniversity of Bergen · NOWestern Norway University of Applied Sciences · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClassification of patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN) into histological classes is useful for predicting a patient's risk of progression to end-stage renal disease (ESRD). However, even in the worst prognostic group, the 5-year end-stage renal disease-free survival rate is as high as 50%.

objectivesTo investigate those prognostic factors indicative of progression to ESRD in patients with ANCA-GN and sclerosing histology.

methodsPatients from the Norwegian Kidney Biopsy Registry between 1991 and 2012 who had biopsy verified pauci-immune glomerulonephritis, positive ANCA serology, and sclerosing histology were included. Cases with ESRD during follow-up were identified via linkage with the Norwegian Renal Registry. Potential prognostic factors with relevant cut-offs were compared in patients with and without progression to ESRD during follow-up.

resultsOf 23 included patients, 10 progressed to ESRD. ESRD patients had a lower initial estimated glomerular filtration rate (eGFR; 21 versus 52 ml/min/1.73 m

conclusionseGFR and percentage of normal glomeruli are strong risk factors for ESRD in ANCA-GN with sclerosing histology.

Identifiers

PMID29973979
PMCPMC6008801
OpenAlexW2805041422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.